A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

BACKGROUND: Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities. METHODS: In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tumours received eribulin mesilate intravenously in 21-day cycles a...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, Chris, Anthoney, Alan, Savulsky, Claudio I., Guo, Matthew, Reyderman, Larisa, Cresti, Nicola, Semiglazov, Vladimir, Timcheva, Constanta, Zubairi, Ishtiaq, Morrison, Rosemary, Plummer, Ruth, Evans, T. R. Jeffry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461928/
https://www.ncbi.nlm.nih.gov/pubmed/30783204
http://dx.doi.org/10.1038/s41416-018-0366-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461928/
https://www.ncbi.nlm.nih.gov/pubmed/30783204
http://dx.doi.org/10.1038/s41416-018-0366-5

Ejemplares similares